International Journal of Alzheimer's Disease

Volume 2012 (2012), Article ID 531646, 6 pages

doi:10.1155/2012/531646

Clinical Study

Efficacy of Music Therapy in Treatment for the Patients with Alzheimer’s Disease

H. Fukui,¹ A. Arai,² and K. Toyoshima¹

¹Department of Education, Nara University of Education, Takabatake, Nara 630-8528, Japan

²Ongakunomori Nonprofit Organization, 1-12 Kobocho, Saidaiji, Nara 631-0827, Japan

Received 5 July 2012; Revised 21 August 2012; Accepted 26 August 2012

Academic Editor: Hiroyuki Umegaki

Copyright © 2012 H. Fukui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

We report that music therapy is effective in the treatment of Alzheimer’s disease. We found that the secretion of 17-estradiol and testosterone, hormones that are supposed to have preventive effects on Alzheimer’s disease, is significantly increased by music therapy. During the sessions, patients with Alzheimer’s disease were allowed to listen to music and songs with verbal contact from the therapist. It was found that problematic behaviors such as poriomania (fugue) had decreased. Music therapy has the potential as an alternative treatment for adverse hormone replacement therapy.

1. Introduction

In both sexes, sex hormone levels decrease with aging. These reductions have been correlated to various symptoms in the elderly including diminished cognitive function, disturbance of memory, mind and mood, depression, and climacteric disturbance [1].

In an attempt to mitigate these symptoms, hormone replacement therapies are administered, for example, estrogen in females and androgen in males [2–4] and females [5, 6]. Even within the elderly population, sex hormone levels are lower in Alzheimer patients than in healthy counterparts [4, 7].

In Alzheimer’s disease, the aging-related reductions in sex hormones, especially estrogen, represent a critical risk factor [8–10]. This is because estrogen protects the nerves and acts to control cell proliferation. Moreover, estrogen decreases the β amyloid peptide content in the neurons which is a typical pathologic finding in Alzheimer’s disease [11, 12] and protects the body from neurotoxicity from β peptide [13, 14]. Estrogen has also shown to suppress the increase and deposition of β-amyloid and to prevent nerve cell damage [12, 15, 16]. In addition to these effects on amyloid metabolism, estrogen improves cognitive function and delays the onset of dementia by increasing cholinergic activity in the brain, stimulating axonal budding and dendrite formation and retarding cerebral arteriosclerosis [9]. Hence, estrogen replacement therapy has been recommended as a prophylaxis of Alzheimer’s disease in particular for the elderly female patients with decreased estrogen levels [8, 17].

In actual clinical settings, estrogen is used to treat postmenopausal women with Alzheimer’s disease and has shown its effect to improve their verbal memory and attention remarkably [18–20]. It has also shown that the onset of dementia is delayed significantly in elderly women who had been receiving estrogen for long periods than those who had not [21–23]. Another report shows that the incidence of Alzheimer’s disease was significantly lower in estrogen recipients than in controls [24]. Estrogen has proved to be effective in the treatment and prevention for Alzheimer’s disease [7].

In recent years, the nerve-protecting action of androgens, especially of testosterone, has been noticed attentively. A study of cortical neurons of cultured rats has shown that testosterone increases NGF (nerve growth factor) and p-75 nerve growth factor receptor and decreases β amyloid peptide in mouse model of Alzheimer’s disease [25, 26]. Similarly, in the human neurons, it has been reported that androgens, such as testosterone, enanthate, methyl testosterone and epitestosterone, suppress nerve apoptosis and protect the nerves [8, 17]. Since the action of testosterone is especially distinct in the portions of the brain that control cognition and memory, the relationship between this hormone and cognitive function has also been investigated. According to Yaffe et al. [27], with the increase in testosterone levels, cognitive test score increases in elderly males. Therefore, prescription of testosterone supplements for males has been suggested as possibly reducing the risk of diminishment of cognitive ability, a prodrome of Alzheimer’s disease. Hence, the reductions in testosterone levels with aging represent a risk factor of Alzheimer’s disease [8, 9]. However, hormone replacement therapy has its drawbacks and is not used today. This topic is discussed later (Section 4).

Recent studies revealed that music is closely associated with hormones which govern the emotion and human behavior, especially with steroid hormones including sex hormones. It has been shown that there is a correlation between spatial ability or music ability and testosterones [28], and listening to music has effects on testosterones and cortisol [29–31]. The correlation between musical ability and spatial cognition has long been known [32–34]. Many studies have investigated the relationship of musical ability to spatial perception and cognition in human being. The assumption that some correlation exists between musical ability and steroid hormones seems to be appropriate. In fact, Hassler discovered that the relationship between T and musical ability (music composition) resembles the one between T and other forms of spatial perception and cognition [33, 35].

Furthermore, the relationship between music and steroid hormones is not limited to musical ability. In the field of behavioral endocrinology and neuroendocrinology, many studies have documented that musical stimulation (listening) affects various biochemical substances [36–38]. In particular, many studies-based findings on C. Experiment had shown that listening to music is effective in alleviating and decreasing stress. In many studies, stress reduction due to music listening has been attributed to reductions in C [39, 40]. It also has been noted that listening to music alters levels of T (increase and decrease) [41, 42]. The research reported that musical activities (listening and playing) adjust steroid secretion in elderly individuals and are likely to alleviate psychological states such as anxiety and tension. Moreover, levels of steroids changing in both directions, increasing in subjects with low hormone levels, and decreasing in subjects with high hormone levels were found [43]. Additionally, there has been a report that listening to the music enhances cognitive recovery of mood after middle cerebral artery stroke, and listening to the music during the early poststroke stage can enhance cognitive recovery and prevent negative mood [44]. Also, music-supported therapy (MST) on patients who had an acute and chronic stroke could bring the neuroplastic changes in the neural circuit underlying audiomotor coupling [44].

2. Materials and Methods

In the present study, we monitored testosterone and 17 β-estradiol levels over time in patients with Alzheimer’s disease stimulated with music, to determine whether music therapy has the potential as an alternative treatment for hormone replacement therapy, focusing on the fact that the hormones bearing a causative relation to the onset of Alzheimer’s disease are also closely related to music.

Traditionally, studies of the efficacy of music therapy in patients with Alzheimer’s disease have focused on changes in symptoms such as dementia most typically and other problematic behaviours: aggressive behaviors, depression, disturbance of mood, and decreased sociality [45–52]. In general, behavioral therapy has shown an alleviation on behavioral deterioration by enhancing the patient’s social interactions, more specifically one to one interactions with carers, therapists, and others [49, 53]. In these studies, mitigation of symptoms was achieved but the mechanism of action remained unexplained.

In music therapy, whether the observed therapeutic effects are attributable to the music, the therapist, or their synergism is often obscure and unidentified. The study population comprised of six patients with an established diagnosis of Alzheimer’s disease (6 females, ages ranging from 67 to 90 years, mean age 81.8 years) residing in a special nursing home for the elderly. Every subject’s family or guardian had received the written informed consent before participating in this study based on the Declaration of Helsinki (1964). The patients were allocated with three conditions (within subjects designs)

(1)The subjects had only been greeted and been questioned upon their health and mood by the therapist. There was no music involved in this condition.(2)12 songs that had been selected in a preliminary survey were sung by the therapist. It was then used for the subjects to listen to.(3)Music therapy that comprises of (1) and  (2).

The session was carried out for the duration of a month, and each session took about an hour. Salivary hormone levels were measured before and after each session. The effects and differences on hormone levels were compared between the before and the after. The therapist contacted the subjects verbaly whose scenarios were formulated prior to the session. A total of 12 songs were selected on the basis of preference by each subject in a preliminary survey. Then, the therapist sang chosen songs without microphone accompanied by the keyboard sound from an amplified speaker. At the same time, each subject’s behavior was evaluated with each condition for three consecutive days: a day before the session, a day of the session, and a day after the session.

Before starting the experiments, a survey was conducted on medical aspects: past history, medication status, and so forth, daily life: lifestyle (possible, but preferably life-style or life style or could use preference of life), daily activity dependence, extent of care, food preference, hobbies, personal relations, communication capability, personality, and other aspects of each subject. Additionally, they were asked of their experiences of performing the music, music-related activities in daily life. Regarding their hearing status, the subjects were examined to have acceptable auditory senses, provided that they retained hearing ability that permits them to have everyday life without difficulty even though the ability had been diminished naturally with aging. None of the subjects were on hormone replacement therapy and known of used any drug use that significantly influence steroid hormones. All subjects had already received music therapy for at least four consecutive months (4 years and 4 months at maximum, 4 months at minimum).

36 samples, 6 subjects before the session and after session three conditions were collected. Saliva samples were kept frozen at −20°C until assayed. Salivary 17 β-estradiol and testosterone levels were assayed in duplicate by EIA kit (Assay Designs, Inc.). The kit is used for the quantitative measurement of 17 β-estradiol (E) and testosterone (T). It occupies a monoclonal antibody to each hormone to bind in a competitive manner, and it targets in a sample or an alkaline phosphatase molecule which has hormones covalently attached to it. The established intra-assay coefficiency of E and T variance was 5.7% and 7.8%, respectively, and the interassay coefficient of variations for E and T is 6.2%, and 9.3%, respectively. The measured intraassay coefficient of variations for E and T was 5.3%, 6.2%, respectively, and the interassay coefficientof variations for E and T were 5.6%, and 7.4%, respectively.

3. Results

Regarding the influence of physical factors involved in the individual conditions, analysis of variance (ANOVA) and -test were employed to determine whether there are differences in duration, tempo, and sound pressure of music between “listening to the music” and “music therapy.” As a result, no such differences were found (, ; , ; , ). Therefore, it can be concluded that there are no differences in physical factors of music conditions between “listening to the music listening” and “music therapy.”

The mean 17 β-estradiol level for the subjects was 253.539 pg/mL. Two-way ANOVA with more than one observation was conducted with “hormonal changes between before and after stimuli” and “group,” “listening to the music,” “therapist,” and “music therapy”—as variables. As a result, statistically significant differences were found in terms of “main effect of group” (, ), “main effect of changes in 17 β-estradiol level” (, ), and “interaction with group” (, ). Although the 17 β-estradiol level increased after the “listening to the music,” the greatest increase was obtained after the “music therapy” (Figure 1). On the other hand, the 17 β-estradiol level decreased after the “therapist” conditioned intervention. A post hoc test (Fisher’s PLSD) revealed a significantly increased 17 β-estradiol level for the “music therapy” condition as compared to the “therapist” condition ().

Figure 1: Changes in 17 β-estradiol concentrations. Changes in 17 β-estradiol concentrations in 6 patients with Alzheimer’s disease at each experimental condition. Two-way ANOVA revealed that the main effect of group (), main effect of changes in 17 β-estradiol level (), and interaction with group () were significant.

The mean testosterone level for the subjects was 450.672 pg/mL. Two-way ANOVA with more than one observation was conducted with “group” under three conditions and “hormonal changes between before and after stimuli” as variables. As a result, statistically significant differences were found in terms of main effect of “group” (, ), main effect of testosterone level changes (, ), and interaction with “group” (, ). A post hoc test (Fisher’s PLSD) revealed a significantly increased testosterone level for the “music therapy” condition as compared to the “music listening” condition () (Figure 2). Carers have reported that problematic behavior was decreased after the “music therapy” condition, and it lasted till a day after the session.

Figure 2: Changes in testosterone concentrations. Changes in testosterone concentrations in 6 patients with Alzheimer’s disease at each experimental condition. Two-way ANOVA revealed that the main effect of group (), main effect of changes in testosterone level (), and interaction with group () were significant.

4. Discussion

These achieved results demonstrate that the “music therapy” condition　increased the testosterone level significantly after stimuli in comparison to the other conditions. Also, the results suggest that problematic behavior can be reduced by music therapy.

Since behavioral therapy involves human relations, it is inevitable that the therapy is strongly dependent on social interactions [49, 51, 53]. In the present study, the effects of “music” and “therapist” were separately evaluated using endocrine indices. It showed that with patients with Alzheimer’s disease at the initial stage, the greatest effect is obtained by “music therapy,” a combination of “therapist” and “listening to the music,” as opposed to the ones being employed alone. The hormones, 17β-estradiol and testosterone that served as indices in this study, have been reported to suppress the degeneration and diminishment of neurofibrils, which a typical character of Alzheimer’s disease is supposed to be caused by. As it was seen in this study, the increases in 17β-estradiol and testosterone levels observed in the patients with Alzheimer’s with diminishing hormones suggest that music therapy may contribute to decelerate the progression of Alzheimer’s disease or even to delay its onset. It is considered that music therapy restores normal hormone levels and suppresses nerve cell damage and protects nerve cells, thus terminating the progression of Alzheimer’s disease.

In general, hormone replacement therapy (HRT) is expected to be highly effective in the prevention and the treatment for Alzheimer’s disease. However, HRT is not applicable to all Alzheimer’s patients as there is risk of causing adverse reactions such as invasive breast cancer, heart disease, and strokes [54]. In fact, there have been a report that adverse reactions were caused in Alzheimer’s patients on HRT. The reactions include increased risks of carcinogenicity in females, feminization in males with estrogen replacement therapy, increased risks of prostatic cancer, elevated cholesterol levels, acne, alopecia, and other symptoms in males receiving testosterone replacement therapy [28, 55]. Therefore, there is a strong demand for a development of an appropriate treatment that can avoid causing such aversive and unwanted reactions [21, 56].

Based on this current study, music therapy seems to be an alternative that is more unlikely to cause risks of harmful reactions to the patients than HRT. The possibility of causing such risks is thought to be significantly lower when music therapy is used than when HRT is used. It is vital to note that no aversive reactions were induced by the music, except music epilepsy [57], which has been reported in a very small percentage of cases. For this reason, music therapy has a potential to become as a safe alternative treatment that is as effective as HRT but with lower prevalence of unwanted reactions. Moreover, music therapy can be expected to serve as an effective prophylaxis of Alzheimer’s disease for the healthy elderly. Music therapy therefore has a potential to be an alternative to HRT hormone replacement therapy for the healthy elderly population.

References

J. M. Daniel, “Estrogens, estrogen receptors, and female cognitive aging: the impact of timing,” Hormones and Behavior. In press

H. Sternbach, “Age-associated testosterone decline in men: clinical issues for psychiatry,” American Journal of Psychiatry, vol. 155, no. 10, pp. 1310–1318, 1998.

S. W. J. Lamberts, A. W. Van Den Beld, and A. J. Van Der Lely, “The endocrinology of aging,” Science, vol. 278, no. 5337, pp. 419–424, 1997.

J. Holland, S. Bandelow, and E. Hogervorst, “Testosterone levels and cognition in elderly men: a review,” Maturitas, vol. 69, no. 4, pp. 322–327, 2011.

S. Rako, “Testosterone deficiency: a key factor in the increased cardiovascular risk to women following hysterectomy or with natural aging?” Journal of Women's Health, vol. 7, no. 7, pp. 825–829, 1998.

E. Hogervorst, C. De Jager, M. Budge, and A. D. Smith, “Serum levels of estradiol and testosterone and performance in different cognitive domains in healthy elderly men and women,” Psychoneuroendocrinology, vol. 29, no. 3, pp. 405–421, 2004.

R. S. Vest and C. J. Pike, “Gender, sex steroid hormones, and Alzheimer's disease,” Hormones and Behavior. In press

J. Hammond, Q. Le, C. Goodyer, M. Gelfand, M. Trifiro, and A. LeBlanc, “Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons,” Journal of Neurochemistry, vol. 77, no. 5, pp. 1319–1326, 2001.

J. J. Manly, C. A. Merchant, D. M. Jacobs et al., “Endogenous estrogen levels and Alzheimer's disease among postmenopausal women,” Neurology, vol. 54, no. 4, pp. 833–837, 2000.

A. M. Barron and C. J. Pike, “Sex hormones, aging, and Alzheimer's disease,” Frontiers in Bioscience (Elite Edition), vol. 4, pp. 976–997, 2012.

H. Xu, G. K. Gouras, J. P. Greenfield et al., “Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides,” Nature Medicine, vol. 4, no. 4, pp. 447–451, 1998.

L. Mateos, T. Persson, S. Katoozi, et al., “Estrogen protects against amyloid-β toxicity by estrogenreceptor α-mediated inhibition of Daxx translocation,” Neuroscience Letters, vol. 506, no. 2, pp. 245–250, 2012.

C. Behl, T. Skutella, F. Lezoualc'h et al., “Neuroprotection against oxidative stress by estrogens: Structure- activity relationship,” Molecular Pharmacology, vol. 51, no. 4, pp. 535–541, 1997.

Y. Goodman and M. P. Mattson, “Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid β-peptide toxicity,” Journal of Neurochemistry, vol. 66, no. 2, pp. 869–872, 1996.

S. Gandy, O. P. Almeida, J. Fonte et al., “Chemical andropause and amyloid-β peptide,” Journal of the American Medical Association, vol. 285, no. 17, pp. 2195–2196, 2001.

V. Kumar, U. N. B. Durai, and T. Jobe, “Pharmacologic management of Alzheimer's disease,” Clinics in Geriatric Medicine, vol. 14, no. 1, pp. 129–146, 1998.

A. Markou, T. Duka, and G. M. Prelevic, “Estrogens and brain function,” Hormones (Athens, Greece), vol. 4, no. 1, pp. 9–17, 2005.

S. Asthana, L. D. Baker, S. Craft et al., “High-dose estradiol improves cognition for women with ad results of a randomized study,” Neurology, vol. 57, no. 4, pp. 605–612, 2001.

I. Wickelgren, “Estrogen stakes claim to cognition,” Science, vol. 276, no. 5313, pp. 675–678, 1997.

D. H. S. Silverman, C. L. Geist, H. A. Kenna et al., “Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD,” Psychoneuroendocrinology, vol. 36, no. 4, pp. 502–513, 2011.

M. X. Tang, D. Jacobs, Y. Stern et al., “Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease,” Lancet, vol. 348, no. 9025, pp. 429–432, 1996.

A. Paganini-Hill and V. W. Henderson, “Estrogen replacement therapy and risk of Alzheimer disease,” Archives of Internal Medicine, vol. 156, no. 19, pp. 2213–2217, 1996.

H. M. Fillit, “The role of hormone replacement therapy in the prevention of Alzheimer disease,” Archives of Internal Medicine, vol. 162, no. 17, pp. 1934–1942, 2002.

S. A. Shumaker, B. A. Reboussin, M. A. Espeland et al., “The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia,” Controlled Clinical Trials, vol. 19, no. 6, pp. 604–621, 1998.

G. K. Gouras, H. Xu, R. S. Gross et al., “Testosterone reduces neuronal secretion of Alzheimer's β-amyloid peptides,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 3, pp. 1202–1205, 2000.

E. R. Rosario, J. Carroll, and C. J. Pike, “Testosterone regulation of Alzheimer-like neuropathology in male 3xTg-AD mice involves both estrogen and androgen pathways,” Brain Research, vol. 1359, pp. 281–290, 2010.

K. Yaffe, L. Y. Lui, J. Zmuda, and J. Cauley, “Sex hormones and cognitive function in older men,” Journal of the American Geriatrics Society, vol. 50, no. 4, pp. 707–712, 2002.

M. Hassler, “Creative musical behavior and sex hormones: musical talent and spatial ability in the two sexes,” Psychoneuroendocrinology, vol. 17, no. 1, pp. 55–70, 1992.

H. Fukui, “Music and testosterone: a new hypothesis for the origin and function of music,” Annals of the New York Academy of Sciences, vol. 930, pp. 448–451, 2001.

H. Fukui and M. Yamashita, “The effects of music and visual stress on testosterone and cortisol in men and women,” Neuroendocrinology Letters, vol. 24, no. 3-4, pp. 173–180, 2003.

H. Fukui and K. Toyoshima, “Music facilitate the neurogenesis, regeneration and repair of neurons,” Medical Hypotheses, vol. 71, no. 5, pp. 765–769, 2008.

M. Hassler and N. Birbaumer, “Musical talent and spatial ability,” Archiv fur Psychologie, vol. 136, no. 3, pp. 235–248, 1984.

M. Hassler, “Creative musical behavior and sex hormones: musical talent and spatial ability in the two sexes,” Psychoneuroendocrinology, vol. 17, no. 1, pp. 55–70, 1992.

G. C. Cupchik, K. Phillips, and D. S. Hill, “Shared processes in spatial rotation and musical permutation,” Brain and Cognition, vol. 46, no. 3, pp. 373–382, 2001.

M. Hassler, “Testosterone and artistic talents,” International Journal of Neuroscience, vol. 56, no. 1–4, pp. 25–38, 1991.

M. Hassler, D. Gupta, and H. Wollmann, “Testosterone, estradiol, ACTH and musical, spatial and verbal performance,” International Journal of Neuroscience, vol. 65, no. 1–4, pp. 45–60, 1992.

S. D. VanderArk and D. Ely, “Cortisol, biochemical, and galvanic skin responses to music stimuli of different preference values by college students in biology and music,” Perceptual and Motor Skills, vol. 77, no. 1, pp. 227–234, 1993.

G. Kreutz, S. Bongard, S. Rohrmann, V. Hodapp, and D. Grebe, “Effects of choir singing or listening on secretory immunoglobulin A, cortisol, and emotional state,” Journal of Behavioral Medicine, vol. 27, no. 6, pp. 623–635, 2004.

S. Khalfa, S. Dalla Bella, M. Roy, I. Peretz, and S. J. Lupien, “Effects of relaxing music on salivary cortisol level after psychological stress,” Annals of the New York Academy of Sciences, vol. 999, pp. 374–376, 2003.

U. M. Nater, E. Abbruzzese, M. Krebs, and U. Ehlert, “Sex differences in emotional and psychophysiological responses to musical stimuli,” International Journal of Psychophysiology, vol. 62, no. 2, pp. 300–308, 2006.

H. Fukui, “Music and testosterone: a new hypothesis for the origin and function of music,” Annals of the New York Academy of Sciences, vol. 930, pp. 448–451, 2001.

H. Fukui and M. Yamashita, “The effects of music and visual stress on testosterone and cortisol in men and women,” Neuroendocrinology Letters, vol. 24, no. 3-4, pp. 173–180, 2003.

H. Fukui, K. Toyoshima, K. Kuda, et al., “The effect of music to sex hormones of elderly person,” Neuroscience Research Supplements, vol. 55, p. S58, 2006.

T. Särkämö, M. Tervaniemi, S. Laitinen et al., “Music listening enhances cognitive recovery and mood after middle cerebral artery stroke,” Brain, vol. 131, no. 3, pp. 866–876, 2008.

L. A. Gerdner, “Effects of individualized versus classical 'relaxation' music on the frequency of agitation in elderly persons with Alzheimer's disease and related disorders,” International Psychogeriatrics, vol. 12, no. 1, pp. 49–65, 2000.

S. B. Hanser and L. W. Thompson, “Effects of a music therapy strategy on depressed older adults,” Journals of Gerontology, vol. 49, no. 6, pp. P265–P269, 1994.

T. R. Lord and J. E. Garner, “Effects of music on Alzheimer patients,” Perceptual and Motor Skills, vol. 76, no. 2, pp. 451–455, 1993.

R. W. Groene, “Effectiveness of music therapy 1 : 1 intervention with individuals having senile dementia of the Alzheimer's type,” Journal of Music Therapy, vol. 30, no. 3, pp. 138–157, 1993.

M. Barinaga, “Alzheimer's treatments that work now,” Science, vol. 282, no. 5391, pp. 1030–1032, 1998.

A. M. Kumar, F. Tims, D. G. Cruess et al., “Music therapy increases serum melatonin levels in patients with Alzheimer's disease,” Alternative Therapies in Health and Medicine, vol. 5, no. 6, pp. 49–57, 1999.

A. M. Cevasco, “Effects of the therapist's nonverbal behavior on participation and affect of individuals with alzheimer's disease during group music therapy sessions,” Journal of Music Therapy, vol. 47, no. 3, pp. 282–299, 2010.

H. B. Svansdottir and J. Snaedal, “Music therapy in moderate and severe dementia of Alzheimer's type: a case-control study,” International Psychogeriatrics, vol. 18, no. 4, pp. 613–621, 2006.

J. Cohen-Mansfield and P. Werner, “Management of verbally disruptive behaviors in nursing home residents,” Journals of Gerontology A, vol. 52, no. 6, pp. M369–M377, 1997.

M. Enserink, “The vanishing promises of hormone replacement,” Science, vol. 297, no. 5580, pp. 325–326, 2002.

N. Nigro and M. Christ-Crain, “Testosterone treatment in the aging male: myth or reality?” Swiss Medical Weekly, p. 142, 2012.

J. Compton, T. Van Amelsvoort, and D. Murphy, “Mood, cognition and Alzheimer's disease,” Best Practice and Research: Clinical Obstetrics and Gynaecology, vol. 16, no. 3, pp. 357–370, 2002.

J. C. M. Brust, “Music and the neurologist: a historical perspective,” Annals of the New York Academy of Sciences, vol. 930, pp. 143–152, 2001.